← back to search

Emanuel Raschi

Northwell Health ·
Area of research
Toxicology · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Medicine, Pharmacovigilance, Drug, Adverse Event Reporting System, Adverse effect, and Pharmacology.
h-index
citations
744
works
12
NIH funding
primary concept
email

Recent publications

The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
Drug Safety 2024cited by 251position: middledoi
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
Drug Safety 2024cited by 169position: middledoi
Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis
Drug Safety 2024cited by 4position: firstdoi
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
Pharmaceuticals 2022cited by 13position: middledoi
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
Cardiovascular Diabetology 2021cited by 65position: middledoi
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region
Frontiers in Pharmacology 2021cited by 24position: middledoi
Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
BMJ Open Diabetes Research & Care 2019cited by 42position: lastdoi
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres
PLoS ONE 2019cited by 3position: middledoi
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System
Expert Opinion on Drug Safety 2018cited by 10position: middledoi
Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
PLoS ONE 2015cited by 67position: middledoi
Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
PLoS ONE 2013cited by 59position: firstdoi
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones
Drug Safety 2012cited by 37position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Elisabetta Poluzzi · University of Bologna8 papers (2012–2024)Fabrizio De Ponti · Northwell Health7 papers (2013–2024)Ippazio Cosimo Antonazzo · University of Pisa3 papers (2018–2021) · 2 papers (2013–2015)Brian Godman · Karolinska Institutet2 papers (2013–2015)Miriam Sturkenboom · University Hospital Heidelberg2 papers (2013–2015) · 2 papers (2013–2015)Gian Paolo Fadini · XinHua Hospital2 papers (2019–2021)Angelo Avogaro · University of Padua2 papers (2019–2021) · 2 papers (2018–2019) · 2 papers (2013–2015) · 2 papers (2012–2019) · 1 papers (2021–2021) · 1 papers (2019–2019) · 1 papers (2021–2021)Eugène van Puijenbroek · AbbVie (United States)1 papers (2024–2024)Laura Gabrielli · University of Ferrara1 papers (2021–2021)Kjetil Bjørnevik · Harvard University1 papers (2018–2018) · 1 papers (2022–2022) · 1 papers (2021–2021)